Results 121 to 130 of about 4,078 (132)

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012
Jaap J M Teunissen, Boen L R Kam, Wouter W De Herder   +2 more
exaly  

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy

European Journal of Nuclear Medicine and Molecular Imaging, 2018
Lisa Bodei, Aviral Singh, Stefano Severi   +2 more
exaly  

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

European Journal of Nuclear Medicine and Molecular Imaging, 2018
Lisa Bodei, Carlo Chiesa, Anna Sarnelli   +2 more
exaly  

Long-term outcome of “Sandwich” chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease

European Journal of Nuclear Medicine and Molecular Imaging, 2020
Rahul V Parghane, Vikas Ostwal, Anant Ramaswamy   +2 more
exaly  

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

European Journal of Nuclear Medicine and Molecular Imaging, 2019
Lisa Bodei, Aviral Singh, Stefano Severi   +2 more
exaly  

Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors

European Journal of Nuclear Medicine and Molecular Imaging, 2015
I M Modlin, S Severi, Silvia Nicolini
exaly  

Long non‐coding RNA PRRT3‐AS1 silencing inhibits prostate cancer cell proliferation and promotes apoptosis and autophagy

Experimental Physiology, 2020
Hai Li, Weihua Wang
exaly  

Repeated cycles of peptide receptor radionuclide therapy (PRRT) – Results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET

Radiotherapy and Oncology, 2012
Jolanta Kunikowska, Leszek Krolicki, Renata Mikołajczak   +2 more
exaly  

The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?

Frontiers in Endocrinology, 2022
exaly  

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

European Journal of Nuclear Medicine and Molecular Imaging, 2014
Lisa Bodei, Mark Kidd, Giovanni Paganelli   +2 more
exaly